Evidence map›Paper›PMID 40264782›Full record

ArticleFrontiers in immunology2025

Treatment of atypical hemolytic uremic syndrome with eculizumab in a patient presenting with neuropsychiatric prodrome: a case report.

Hanze Yang, Jingdong Zhang, Hao Wu, Hongzhao Xu, Zhonggao Xu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hanze YangDepartment of Nephrology, The First Hospital of Jilin University, Changchun, Jilin, China.
Jingdong ZhangDepartment of Nephrology, The First Hospital of Jilin University, Changchun, Jilin, China.
Hao WuDepartment of Nephrology, The First Hospital of Jilin University, Changchun, Jilin, China.
Hongzhao XuDepartment of Nephrology, The First Hospital of Jilin University, Changchun, Jilin, China.
Zhonggao XuDepartment of Nephrology, The First Hospital of Jilin University, Changchun, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy (TMA) caused by dysregulation of the complement system. It is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Owing to its diverse and nonspecific clinical manifestations, early diagnosis of the condition is challenging and typically requires excluding other TMA-related conditions, such as thrombotic thrombocytopenic purpura and hemolytic uremic syndrome caused by

Indexed as

Antibodies, Monoclonal, HumanizedAtypical Hemolytic Uremic SyndromeComplement Inactivating AgentsFemaleHumansPlasma ExchangeRenal DialysisTreatment OutcomeAntibodies, Monoclonal, HumanizedComplement Inactivating Agentseculizumabatypical hemolytic uremic syndromeeculizumabintermittent seizuresneuropsychiatric prodromeposterior reversible encephalopathy syndromethrombotic microangiopathy

Identifiers

PMID40264782
PMCPMC12011752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.